ATR and non-small cell lung carcinoma: In the current study, we retrospectively investigated 191 NSCLC patients with pathogenic or likely pathogenic ATM/ATR mutations using large-panel next-generation sequencing (NGS), and the result was then compared with that of 308 NSCLC patients without any types of ATM/ATR variants to elucidate the PIKK aberration-associated clinical and genomic features.